ICW Investment Advisors LLC Has $247,000 Holdings in Eli Lilly and Company (NYSE:LLY)

ICW Investment Advisors LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 9.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 423 shares of the company’s stock after acquiring an additional 38 shares during the quarter. ICW Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $247,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Lipe & Dalton acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $27,000. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company during the third quarter worth $35,000. Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company during the third quarter worth $36,000. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company during the third quarter worth $40,000. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

NYSE LLY opened at $776.75 on Thursday. Eli Lilly and Company has a 52 week low of $399.26 and a 52 week high of $800.78. The firm has a market capitalization of $738.04 billion, a P/E ratio of 114.40, a PEG ratio of 1.58 and a beta of 0.37. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a 50-day moving average price of $762.03 and a 200-day moving average price of $669.96.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the prior year, the firm earned $1.62 EPS. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 13.5 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.